[go: up one dir, main page]

NO20021821D0 - Natrium-hydrogen utvekslingstype 1 inhibitor krystaller - Google Patents

Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Info

Publication number
NO20021821D0
NO20021821D0 NO20021821A NO20021821A NO20021821D0 NO 20021821 D0 NO20021821 D0 NO 20021821D0 NO 20021821 A NO20021821 A NO 20021821A NO 20021821 A NO20021821 A NO 20021821A NO 20021821 D0 NO20021821 D0 NO 20021821D0
Authority
NO
Norway
Prior art keywords
sodium
exchange type
hydrogen exchange
inhibitor crystals
crystals
Prior art date
Application number
NO20021821A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021821L (no
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20021821L publication Critical patent/NO20021821L/no
Publication of NO20021821D0 publication Critical patent/NO20021821D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
NO20021821A 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller NO20021821D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (2)

Publication Number Publication Date
NO20021821L NO20021821L (no) 2002-04-18
NO20021821D0 true NO20021821D0 (no) 2002-04-18

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021821A NO20021821D0 (no) 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Country Status (44)

Country Link
EP (1) EP1224179B1 (et)
JP (1) JP2003512455A (et)
KR (1) KR100464526B1 (et)
CN (2) CN1636991A (et)
AP (1) AP2002002493A0 (et)
AR (1) AR029402A1 (et)
AT (1) ATE271047T1 (et)
AU (1) AU778573B2 (et)
BG (1) BG106729A (et)
BR (1) BR0015275A (et)
CA (1) CA2389020A1 (et)
CO (1) CO5271714A1 (et)
CZ (1) CZ20021332A3 (et)
DE (1) DE60012208T2 (et)
DK (1) DK1224179T3 (et)
DZ (1) DZ3463A1 (et)
EA (1) EA004937B1 (et)
EE (1) EE200200227A (et)
ES (1) ES2222923T3 (et)
GE (1) GEP20043222B (et)
GT (1) GT200000180A (et)
HK (1) HK1048472B (et)
HR (1) HRP20020366B1 (et)
HU (1) HUP0204009A3 (et)
IL (1) IL148581A0 (et)
IS (1) IS6302A (et)
MA (1) MA26840A1 (et)
MX (1) MXPA02004358A (et)
NO (1) NO20021821D0 (et)
NZ (1) NZ517738A (et)
OA (1) OA12080A (et)
PA (1) PA8505501A1 (et)
PE (1) PE20010764A1 (et)
PL (1) PL354869A1 (et)
PT (1) PT1224179E (et)
SI (1) SI1224179T1 (et)
SK (1) SK5312002A3 (et)
SV (1) SV2002000209A (et)
TN (1) TNSN00210A1 (et)
TR (1) TR200201167T2 (et)
UA (1) UA72002C2 (et)
WO (1) WO2001030759A2 (et)
YU (1) YU31502A (et)
ZA (1) ZA200203295B (et)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
CZ20032017A3 (cs) * 2001-01-31 2004-05-12 Pfizeráproductsáinc Ethanoláty inhibitoru sodík@vodík měniče typu �Ź způsob jejich přípravyŹ jejich použití a farmaceutický prostředekŹ který je obsahuje
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
BR0309707A (pt) * 2002-05-02 2005-02-09 Pfizer Prod Inc Tratamento de diabetes e complicações diabéticas com inibidores nhe-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
WO2001030759A3 (en) 2001-09-13
CZ20021332A3 (cs) 2002-10-16
ES2222923T3 (es) 2005-02-16
AU778573B2 (en) 2004-12-09
NZ517738A (en) 2005-06-24
ZA200203295B (en) 2003-06-25
IL148581A0 (en) 2002-09-12
JP2003512455A (ja) 2003-04-02
HUP0204009A2 (hu) 2003-03-28
HRP20020366A2 (en) 2004-02-29
ATE271047T1 (de) 2004-07-15
EA200200416A1 (ru) 2002-10-31
KR20020040918A (ko) 2002-05-30
CO5271714A1 (es) 2003-04-30
BG106729A (bg) 2002-12-29
AP2002002493A0 (en) 2002-06-30
CN1384829A (zh) 2002-12-11
SV2002000209A (es) 2002-07-16
DK1224179T3 (da) 2004-10-25
DZ3463A1 (fr) 2001-05-03
NO20021821L (no) 2002-04-18
DE60012208D1 (de) 2004-08-19
PT1224179E (pt) 2004-10-29
EE200200227A (et) 2003-06-16
EP1224179B1 (en) 2004-07-14
HK1048472A1 (en) 2003-04-04
TR200201167T2 (tr) 2002-08-21
GEP20043222B (en) 2004-04-26
HRP20020366B1 (en) 2005-04-30
OA12080A (en) 2003-08-25
UA72002C2 (en) 2005-01-17
TNSN00210A1 (fr) 2005-11-10
WO2001030759A2 (en) 2001-05-03
BR0015275A (pt) 2002-07-16
PA8505501A1 (es) 2003-09-05
AU7441500A (en) 2001-05-08
CN1205205C (zh) 2005-06-08
SK5312002A3 (en) 2003-01-09
PE20010764A1 (es) 2001-07-23
CN1636991A (zh) 2005-07-13
CA2389020A1 (en) 2001-05-03
DE60012208T2 (de) 2005-07-21
EA004937B1 (ru) 2004-10-28
EP1224179A2 (en) 2002-07-24
GT200000180A (es) 2002-04-11
IS6302A (is) 2002-03-15
YU31502A (sh) 2004-12-31
MXPA02004358A (es) 2002-11-07
HK1048472B (zh) 2005-09-16
HUP0204009A3 (en) 2004-07-28
SI1224179T1 (en) 2004-10-31
MA26840A1 (fr) 2004-12-20
PL354869A1 (en) 2004-03-08
AR029402A1 (es) 2003-06-25
KR100464526B1 (ko) 2005-01-03

Similar Documents

Publication Publication Date Title
ATE245142T1 (de) No-synthase inhibitoren
EE200200273A (et) Uudsed diabeedivastased agensid
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
NO20004212L (no) Kjølesystem
DE69924306D1 (de) Wärmetauscher
DE69915289D1 (de) Kühlvorrichtung
NO20004213L (no) Kjølesystem
DE10083636T1 (de) Wärmetauscher
DK1216284T3 (da) R 22-erstatningskölemiddel
DE59910800D1 (de) Kühler
DE50005074D1 (de) Flüssigkristallines Medium
DE60027489D1 (de) Wärmetauscher
EP1067925A4 (en) ANTIDIABETIC CONNECTIONS
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ID27766A (id) Garam-garam paroksetin
DE69824454D1 (de) Wärmetauscher
NO20021821D0 (no) Natrium-hydrogen utvekslingstype 1 inhibitor krystaller
NO20025132D0 (no) Natrium-hydrogen-byttertype 1-inhibitor (NHE-1)
DE59905017D1 (de) Wärmeübertrager
ID27904A (id) Metode untuk menyiapkan inhibitor penukar natrium-hidrogen tipe 1
FI981909A0 (fi) Lämmönsiirrin
EP1165598A4 (en) INHIBITOR FOR HOOKWorm BLOOD PLATES
ATA200698A (de) Wärmetauscher
KR950024082U (ko) 교환기용 보호기반
ATA58798A (de) Wärmetauscherblock

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application